Hemispherx BioPharma, Inc. (NYSE American: HEB) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of immunotherapeutic products. The company’s primary activities center on researching and advancing compounds designed to modulate the immune system in order to treat viral infections, cancer, and other immune‐related disorders. Hemispherx BioPharma’s two lead candidates—Ampligen® (rintatolimod) and Alferon® N Injection—are being investigated for their potential to stimulate innate immune responses and support traditional antiviral and anticancer therapies.
Ampligen®, a toll‐like receptor 3 agonist, has been evaluated in multiple clinical trials for chronic fatigue syndrome, cancer immunotherapy combinations, and emerging viral threats. The compound is designed to broadly activate antiviral defense mechanisms, making it a candidate for both rare diseases and potential pandemic preparedness. Alferon® N Injection, a naturally derived interferon alpha formulation, has been used under limited approval for certain HPV‐related conditions and is under further study for its efficacy against viral and oncological indications.
Founded in 1981 and headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma operates research laboratories in the United States and maintains strategic collaborations with federal and academic institutions. The company has engaged in partnerships with agencies such as the U.S. Department of Defense and the National Institutes of Health to support preclinical and clinical programs. Through these alliances, Hemispherx aims to leverage government-sponsored research and expedite the development timelines for its immunotherapeutic candidates.
Under the leadership of its President and Chief Executive Officer, the company draws on a management team with extensive experience in biotechnology development and regulatory affairs. Scientific advisors and board members bring expertise in clinical trial design, pharmaceutical manufacturing, and commercialization strategies. As Hemispherx BioPharma advances its clinical pipeline, the organization remains committed to addressing unmet medical needs in immunology and infectious diseases.
AI Generated. May Contain Errors.
